Clinical trial
Lucentis for Inflammatory Macular Edema Trial
NCT00498355 · University of California, San Francisco, Other · Completed
Key facts
| NCT number | NCT00498355 |
|---|---|
| Title | Lucentis for Inflammatory Macular Edema Trial |
| Official title | Effect of Ranibizumab on Refractory Macular Edema in Uveitis |
| Acronym | LIME |
| Lead sponsor | University of California, San Francisco, Other |
| Collaborators | Genentech, Inc. Industry |
| Status | Completed |
| Phase | Phase 1/Phase 2 |
| Study type | Interventional |
| Conditions | Uveitis, Cytoid Macular Edema |
| Intervention type | Drug |
| Interventions | Ranibizumab |
| Enrollment | 7 |
| Start date | Jul 1, 2007 |
| Primary completion | Jan 1, 2009 |
| Completion | Dec 1, 2009 |
| First posted | Jul 10, 2007 |
| Last update posted | Nov 30, 2017 |
| Countries | United States |
At a glance
- 1–9 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: